MX2019009537A - Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa). - Google Patents
Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).Info
- Publication number
- MX2019009537A MX2019009537A MX2019009537A MX2019009537A MX2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A MX 2019009537 A MX2019009537 A MX 2019009537A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- ampa receptor
- disorders
- treatment
- receptor potentiators
- Prior art date
Links
- 102000003678 AMPA Receptors Human genes 0.000 title abstract 2
- 108090000078 AMPA Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
La invencion proporciona compuestos de formula (I): (ver formula) (I) en donde R1 y R2 se definen en la especificacion, a composiciones farmaceuticas que comprenden los compuestos y los compuestos para usarse como medicamentos; los compuestos potencian la funcion del receptor de AMPA y se espera que sean utiles en el tratamiento de trastornos del sistema nervioso central, por ejemplo en el tratamiento de trastornos depresivos, trastornos del estado de animo y disfuncion cognitiva asociados con trastornos neuropsiquiatricos tales como la esquizofrenia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1702221.1A GB201702221D0 (en) | 2017-02-10 | 2017-02-10 | Compounds |
| PCT/GB2018/050370 WO2018146486A1 (en) | 2017-02-10 | 2018-02-09 | Ampa receptor potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019009537A true MX2019009537A (es) | 2019-10-04 |
Family
ID=58462168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019009537A MX2019009537A (es) | 2017-02-10 | 2018-02-09 | Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186567B2 (es) |
| EP (1) | EP3580213B1 (es) |
| JP (1) | JP7014808B2 (es) |
| KR (1) | KR102665887B1 (es) |
| CN (1) | CN110520418B (es) |
| AU (1) | AU2018218307C1 (es) |
| ES (1) | ES2974824T3 (es) |
| GB (1) | GB201702221D0 (es) |
| MX (1) | MX2019009537A (es) |
| NZ (1) | NZ755747A (es) |
| RU (1) | RU2019126574A (es) |
| WO (1) | WO2018146486A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
| WO2024255822A1 (zh) * | 2023-06-15 | 2024-12-19 | 上海魁特迪生物科技有限公司 | Dir结合剂及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| NZ522773A (en) | 2000-06-12 | 2005-06-24 | Eisai Co Ltd | 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof |
| AU2003302027A1 (en) | 2002-11-21 | 2004-06-15 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| WO2006109056A1 (en) | 2005-04-12 | 2006-10-19 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| CA2646585A1 (en) | 2006-03-20 | 2007-09-27 | Glaxo Group Limited | Compounds which potentiate ampa receptor and uses thereof in medicine |
| ES2378574T3 (es) | 2006-04-24 | 2012-04-16 | Eli Lilly & Company | Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1 |
| TW200817385A (en) * | 2006-07-04 | 2008-04-16 | Organon Nv | Heterocyclic derivatives |
| ATE502675T1 (de) * | 2006-11-03 | 2011-04-15 | Glaxo Group Ltd | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin |
| GB0711089D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| GB0711088D0 (en) * | 2007-06-08 | 2007-07-18 | Glaxo Group Ltd | Compounds |
| JP5470557B2 (ja) | 2007-07-26 | 2014-04-16 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤の合成 |
| BRPI0815957A2 (pt) | 2007-09-20 | 2019-09-24 | Cortex Pharma Inc | "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas" |
| GB0721094D0 (en) | 2007-10-26 | 2007-12-05 | Glaxo Group Ltd | Compounds |
| TW200934497A (en) | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
| WO2009134392A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| TW201012803A (en) * | 2008-06-06 | 2010-04-01 | Organon Nv | Heterocyclic derivatives |
| TW201031649A (en) | 2008-12-02 | 2010-09-01 | Organon Nv | 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives |
| DK2445883T3 (da) | 2009-06-26 | 2014-10-13 | Pfizer | Heterocykliske sulfonamider, anvendelser og farmaceutiske sammensætniger deraf |
| WO2011132051A2 (en) | 2010-04-19 | 2011-10-27 | Glenmark Pharmaceuticals S.A. | Tricycle compounds as phosphodiesterase-10 inhibitors |
| UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
| GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
| GB201803340D0 (en) | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
-
2017
- 2017-02-10 GB GBGB1702221.1A patent/GB201702221D0/en not_active Ceased
-
2018
- 2018-02-09 KR KR1020197024520A patent/KR102665887B1/ko active Active
- 2018-02-09 RU RU2019126574A patent/RU2019126574A/ru unknown
- 2018-02-09 AU AU2018218307A patent/AU2018218307C1/en active Active
- 2018-02-09 MX MX2019009537A patent/MX2019009537A/es unknown
- 2018-02-09 WO PCT/GB2018/050370 patent/WO2018146486A1/en not_active Ceased
- 2018-02-09 ES ES18705480T patent/ES2974824T3/es active Active
- 2018-02-09 JP JP2019543832A patent/JP7014808B2/ja active Active
- 2018-02-09 NZ NZ755747A patent/NZ755747A/en unknown
- 2018-02-09 US US16/482,791 patent/US11186567B2/en active Active
- 2018-02-09 CN CN201880023973.3A patent/CN110520418B/zh active Active
- 2018-02-09 EP EP18705480.4A patent/EP3580213B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2974824T3 (es) | 2024-07-01 |
| AU2018218307B2 (en) | 2022-02-24 |
| RU2019126574A (ru) | 2021-03-10 |
| CA3051647A1 (en) | 2018-08-16 |
| EP3580213A1 (en) | 2019-12-18 |
| NZ755747A (en) | 2022-02-25 |
| EP3580213C0 (en) | 2024-03-27 |
| WO2018146486A1 (en) | 2018-08-16 |
| RU2019126574A3 (es) | 2021-03-29 |
| US20210139463A1 (en) | 2021-05-13 |
| KR102665887B1 (ko) | 2024-05-10 |
| JP7014808B2 (ja) | 2022-02-01 |
| KR20190117549A (ko) | 2019-10-16 |
| AU2018218307A1 (en) | 2019-08-15 |
| BR112019016603A2 (pt) | 2020-03-31 |
| AU2018218307C1 (en) | 2022-06-23 |
| US11186567B2 (en) | 2021-11-30 |
| JP2020507592A (ja) | 2020-03-12 |
| CN110520418A (zh) | 2019-11-29 |
| CN110520418B (zh) | 2022-08-16 |
| GB201702221D0 (en) | 2017-03-29 |
| EP3580213B1 (en) | 2024-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501570B1 (en) | Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| PH12016501791A1 (en) | Muscarinic receptor agonists | |
| PH12017500252A1 (en) | New spiro[3h-indole-3,2`-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors | |
| JO3316B1 (ar) | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| GEP20207149B (en) | Allosteric modulators of nicotinic acetylcholine receptors | |
| PH12016501624A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| GEP20227344B (en) | Pyrimidine compound as jak kinase inhibitor | |
| GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
| CL2018001085A1 (es) | Derivados de indolin-2-ona | |
| MY201535A (en) | Therapeutic compounds | |
| PH12016501393A1 (en) | Substituted bicyclic heteroaryl compounds as rxr agonists | |
| MX2019009537A (es) | Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa). | |
| ZA202001295B (en) | Thiazolopyridine derivatives as adenosine receptor antagonists | |
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
| MX2020009097A (es) | Compuestos que modulan la funcion del receptor de ampa. | |
| MX2018004256A (es) | Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos. | |
| MX2017015300A (es) | Derivados de aminoesteres. | |
| PH12017501209A1 (en) | Heterocyclylalkyne derivatives and their use as modulators of mglur5 receptors | |
| PH12019550251A1 (en) | HETEROCYCLYLMETHYLIDENE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS | |
| GB2519470A (en) | Bicyclic aza compounds as muscarinic M1 receptor agonists | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| MX2017007648A (es) | Composicion farmaceutica que comprende compuesto biciclico de amida heterociclica aromatica que contiene nitrogeno como ingrediente activo. |